Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 16, 2026

Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider

View original at globenewswire.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence

  • Laparoscopic Surgery dominated with 36.58% in 2025 due to its widespread adoption, proven safety, and effectiveness

    80% confidence

  • Minimally invasive techniques, including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound, have seen adoption rates rise by more than 60% in the past five years

    80% confidence

  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence

  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033

    80% confidence

  • The uterine fibroid market will grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence

  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence

  • Minimally invasive techniques including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound have seen adoption rates rise by more than 60% in the past five years

    80% confidence

  • Surgical Procedures dominated with 38.45% market share in 2025

    80% confidence

  • The Uterine Fibroid Market will grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence

  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence

  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence

  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence

  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence

  • Hospitals & Clinics dominated with 47.49% market share in 2025

    80% confidence

  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence

  • Minimally invasive techniques, including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound, have seen adoption rates rise by more than 60% in the past five years

    80% confidence

  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence

  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence

  • Hospitals & Clinics dominated with 47.49% in 2025 due to their advanced infrastructure and specialized care

    80% confidence

  • African American women have a high risk of uterine fibroids, occurring at a younger age with severe symptoms compared to other ethnicities

    80% confidence

  • Laparoscopic Surgery dominated with 36.58% market share in 2025

    80% confidence

  • Uterine fibroids are common among women between the ages of 30 to 40 years

    80% confidence

  • Uterine fibroids are common among women between the ages of 30 to 40 years, with varying rates among different ethnic groups

    80% confidence

  • MRI-Guided Focused Ultrasound expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence

  • Submucosal Fibroids dominated with 36.24% in 2025 due to their high prevalence and significant symptom severity

    80% confidence

  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence

  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence

  • The U.S. Uterine Fibroid Market size was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25%

    80% confidence

  • Laparoscopic Surgery dominated with 36.58% market share in 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider — Source | Via News | ViaNews EU